SEZ6-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ABBV-011 / AbbVie
NCT06125327: SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2/3
210
RoW
SC1011, Active Drug, Placebo comparator, comparator
Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis
12/25
12/25
NCT06160440: The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.

Completed
1
55
RoW
SC1011
Guangzhou JOYO Pharma Co., Ltd
Diopathic Pulmonary Fibrosis, Pulmonary Fibrosis
09/21
02/22
NCT06135363: Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects

Completed
1
45
RoW
SC1011, experimental drug group, Placebo tablet, Control Group
Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis
01/23
01/23
NCT03639194: A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Completed
1
132
Japan, US, RoW
ABBV-011, SC-011, Budigalimab, ABBV-181
AbbVie
Small Cell Lung Cancer
01/24
01/24
ABBV-706 / AbbVie
M23-385, NCT05599984: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Recruiting
1
350
Europe, Japan, US, RoW
ABBV-706, Cisplatin, Budigalimab, ABBV-181, Carboplatin
AbbVie
Advanced Solid Tumors
10/25
05/27

Download Options